The Medicrea Group announced sales results for the month, quarter and six months ended June 2018. Sales for the first half of 2018 amounted to €16.9 million, up 22% at constant exchange rates compared to the first half of 2017.

Second quarter sales reached €8.8 million, a new historic performance following the previous record of €8.2 million in the first quarter of 2018.

The month of June 2018 shows the best performance of the year with sales for an amount of €3.4 million, reflecting the resumption of strong growth from the very beginning of 2018.

The company provided earnings guidance for the full year of fiscal 2018. The company announced that it is confident in pursuing growth throughout the second half of the year, particularly in the United States, by deploying new services and products for the personalized treatment of spinal pathologies and should be on track to be EBITDA positive during 2018.